Repros Therapeutics, Inc. (RPRX) Posts Wider than Expected Q2 Loss of 21c/Share

Repros Therapeutics, Inc. (NASDAQ: RPRX) reported Q2 EPS of ($0.21), $0.02 worse than the analyst estimate of ($0.19).

For earnings history and earnings-related data on Repros Therapeutics, Inc. (RPRX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Iridium Communications (IRDM) Reports In-Line Q1 EPS; offers outlook
• U.S. Bancorp (USB) PT Lowered to $54 at Oppenheimer
• Blackstone (BX) Tops Q1 EPS by 1c